NASDAQ:NKTR

Nektar Therapeutics (NKTR) Stock Forecast, Price & News

$0.60

-0.01 (-1.65%)

(As of 09/29/2023 ET)

Compare

Today's Range: $0.58
▼
$0.62
50-Day Range: $0.51
▼
$1.05
52-Week Range: $0.51
▼
$4.37

Volume: 1.51 million shs
Average Volume: 1.47 million shs
Market Capitalization: $113.24 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.00

Nektar Therapeutics MarketRank™ Forecast

Analyst Rating: Reduce
1.80 Rating Score
Upside/Downside: 403.7% Upside
$3.00 Price Target
Short Interest: Healthy
3.82% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.77
Upright™ Environmental Score
News Sentiment: 0.44
Based on 2 Articles This Week
Insider Trading: Selling Shares
$26,174 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.00) to ($0.77) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.22 out of 5 stars

Medical Sector

398th out of 972 stocks

Pharmaceutical Preparations Industry

170th out of 445 stocks

2.9

Analyst's Opinion

Consensus Rating
Nektar Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.80, and is based on no buy ratings, 4 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $3.00, Nektar Therapeutics has a forecasted upside of 403.7% from its current price of $0.60.
Amount of Analyst Coverage
Nektar Therapeutics has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
3.82% of the outstanding shares of Nektar Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Nektar Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Nektar Therapeutics has recently increased by 7.08%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Nektar Therapeutics does not currently pay a dividend.
Dividend Growth
Nektar Therapeutics does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Nektar Therapeutics has received a 60.23% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Topoisomerase 1 (TOP1) inhibitors", "Clinical research services", and "Peripheral opioid receptor antagonists" products. See details.
Environmental Sustainability
The Environmental Impact score for Nektar Therapeutics is -1.77.

1.4

News and Social Media Coverage

News Sentiment
Nektar Therapeutics has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Nektar Therapeutics this week, compared to 2 articles on an average week.
Search Interest
Only 9 people have searched for NKTR on MarketBeat in the last 30 days. This is a decrease of -18% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Nektar Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Nektar Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $26,174.00 in company stock.
Percentage Held by Insiders
Only 3.07% of the stock of Nektar Therapeutics is held by insiders.
Percentage Held by Institutions
82.20% of the stock of Nektar Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Nektar Therapeutics are expected to grow in the coming year, from ($1.00) to ($0.77) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Nektar Therapeutics is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Nektar Therapeutics is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Nektar Therapeutics has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Nektar Therapeutics (NASDAQ:NKTR) Stock

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

NKTR Price History

30 days | 90 days | 365 days | Advanced Chart

NKTR Stock News Headlines

September 27, 2023 | finance.yahoo.com

Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer

September 21, 2023 | benzinga.com

Director at Nektar Therapeutics Acquires Company Stock Options Worth 85,000 Shares

October 1, 2023 | Legacy Research (Ad)

WARNING: Mandatory U.S. Dollar Recall is Weeks Away

If you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.

September 21, 2023 | benzinga.com

Nektar Therapeutics Board Member Awarded $59K Worth of Stock Options

September 13, 2023 | markets.businessinsider.com

Nektar Therapeutics Reports Promising Data From Phase 1b Study Of Rezpegaldesleukin

September 7, 2023 | finance.yahoo.com

Why Is Nektar (NKTR) Down 37.1% Since Last Earnings Report?

September 6, 2023 | finance.yahoo.com

Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th

August 18, 2023 | gurufocus.com

RA Capital Management, L.P. Acquires Significant Stake in Nektar Therapeutics

October 1, 2023 | Chaikin Analytics (Ad)

This Stock Could Go Up 66% or More.

Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.

August 9, 2023 | finance.yahoo.com

Nektar Therapeutics (NKTR) Q2 Loss Narrows, Sales Miss

August 8, 2023 | markets.businessinsider.com

Nektar Therapeutics Q2 Loss decreases, beats estimates

August 8, 2023 | finance.yahoo.com

Nektar Therapeutics Reports Second Quarter 2023 Financial Results

August 8, 2023 | msn.com

Mizuho Reiterates Nektar Therapeutics (NKTR) Neutral Recommendation

August 7, 2023 | proactiveinvestors.com

Nektar stock soars on new data for rezpeg after Eli Lilly got it wrong

August 7, 2023 | benzinga.com

Why Is Nektar Therapeutics Stock Surging Today?

August 7, 2023 | reuters.com

Nektar Therapeutics sues Eli Lilly over autoimmune disease treatment

August 7, 2023 | finance.yahoo.com

Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company

August 1, 2023 | finance.yahoo.com

Nektar to Announce Financial Results for the Second Quarter 2023 on Tuesday, August 8, 2023, After Close of U.S.-Based Financial Markets

July 16, 2023 | finance.yahoo.com

Nektar Therapeutics (NASDAQ:NKTR) is largely controlled by institutional shareholders who own 70% of the company

July 11, 2023 | gurufocus.com

Citadel Advisors LLC Acquires Significant Stake in Nektar Therapeutics

July 1, 2023 | finanznachrichten.de

Nektar Regains Full Rights Of REZPEG From Eli Lilly, Plans To Initiate Phase 2b Study

June 12, 2023 | finance.yahoo.com

Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference

June 8, 2023 | finance.yahoo.com

Why Is Nektar (NKTR) Down 19.7% Since Last Earnings Report?

June 8, 2023 | finance.yahoo.com

Investors Don't See Light At End Of Nektar Therapeutics' (NASDAQ:NKTR) Tunnel

May 26, 2023 | bizjournals.com

Howard Robin seeks another turnaround at Nektar

May 11, 2023 | msn.com

Jefferies Upgrades Nektar Therapeutics (NKTR)

May 10, 2023 | finance.yahoo.com

Nektar Therapeutics (NASDAQ:NKTR) Q1 2023 Earnings Call Transcript

See More Headlines

Receive NKTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NKTR Company Calendar

Last Earnings: 8/08/2023
Today: 9/30/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Sector: Medical
Current Symbol: NASDAQ:NKTR
CUSIP: 64026810
CIK: 906709
Web: www.nektar.com
Phone: (415) 482-5300
Fax: 415-339-5300
Employees: 216
Year Founded: 1990

Price Target and Rating

Average Stock Price Forecast: $3.00
High Stock Price Forecast: $6.00
Low Stock Price Forecast: $1.00
Forecasted Upside/Downside: +403.7%
Consensus Rating: Reduce
Rating Score (0-4): 1.80
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.63)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-368,200,000.00
Net Margins: -349.75%
Pretax Margin: -346.47%
Return on Equity: -67.03%
Return on Assets: -32.01%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.70
Quick Ratio: 8.29

Sales & Book Value

Annual Sales: $92.06 million
Price / Sales: 1.23
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.95 per share
Price / Book: 0.31

Miscellaneous

Outstanding Shares: 190,120,000
Free Float: 184,282,000
Market Cap: $113.24 million
Optionable: Optionable
Beta: 1.00

Social Links

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Mr. Howard W. Robin (Age 70)
CEO, Pres & Director
Comp: $1.83M

Mr. Mark A. Wilson (Age 51)
Sr. VP, Chief Legal Officer & Sec.
Comp: $749.99k

Dr. Jonathan Zalevsky Ph.D. (Age 48)
Sr. VP & Chief R&D Officer
Comp: $1.25M

Ms. Sandra A. Gardiner (Age 57)
Chief Financial Officer

Vivian Wu
Director of Investor Relations & Corp. Affairs

Mr. Robert Bacci
Sr. VP of HR & Facilities Operations

Ms. Jennifer Ruddock
Chief Bus. Officer

Dr. Mary Tagliaferri L.Ac. (Age 57)
M.D., Chief Medical Officer

Dr. Loui T. Madakamutil
VP and Head of Discovery & Research

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NKTR Stock - Frequently Asked Questions

Should I buy or sell Nektar Therapeutics stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last twelve months. There are currently 1 sell rating and 4 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "reduce" NKTR shares.
View NKTR analyst ratings or view top-rated stocks.
What is Nektar Therapeutics' stock price forecast for 2023?: 5 Wall Street research analysts have issued 12 month target prices for Nektar Therapeutics' shares. Their NKTR share price forecasts range from $1.00 to $6.00. On average, they anticipate the company's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 403.7% from the stock's current price.
View analysts price targets for NKTR or view top-rated stocks among Wall Street analysts.
How have NKTR shares performed in 2023?: Nektar Therapeutics' stock was trading at $2.26 at the beginning of 2023. Since then, NKTR shares have decreased by 73.6% and is now trading at $0.5956.
View the best growth stocks for 2023 here.
When is Nektar Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our NKTR earnings forecast.
How were Nektar Therapeutics' earnings last quarter?: Nektar Therapeutics (NASDAQ:NKTR) issued its earnings results on Tuesday, August, 8th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.30) by $0.03. The biopharmaceutical company had revenue of $20.50 million for the quarter, compared to the consensus estimate of $20.94 million. Nektar Therapeutics had a negative trailing twelve-month return on equity of 67.03% and a negative net margin of 349.75%. During the same period last year, the business earned ($0.85) EPS.
What is Howard W. Robin's approval rating as Nektar Therapeutics' CEO?: 46 employees have rated Nektar Therapeutics Chief Executive Officer Howard W. Robin on Glassdoor.com. Howard W. Robin has an approval rating of 81% among the company's employees.

What other stocks do shareholders of Nektar Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY), Netflix (NFLX) and Incyte (INCY).
What is Nektar Therapeutics' stock symbol?: Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."
How do I buy shares of Nektar Therapeutics?: Shares of NKTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Nektar Therapeutics' stock price today?: One share of NKTR stock can currently be purchased for approximately $0.60.
How much money does Nektar Therapeutics make?: Nektar Therapeutics (NASDAQ:NKTR) has a market capitalization of $113.24 million and generates $92.06 million in revenue each year. The biopharmaceutical company earns $-368,200,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis.
How many employees does Nektar Therapeutics have?: The company employs 216 workers across the globe.
How can I contact Nektar Therapeutics?: Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The official website for the company is www.nektar.com. The biopharmaceutical company can be reached via phone at (415) 482-5300, via email at investors@nektar.com, or via fax at 415-339-5300.

This page (NASDAQ:NKTR) was last updated on 10/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial